According to a recent announcement, a much anticipated human immunodeficiency virus (HIV) vaccine clinical trial that began in December 2020 has been discontinued in Africa because there is little or no chance of the trial demonstrating vaccine efficacy in preventing HIV acquisition.
On December 6, 2023, the PrEPVacc clinical trial leadership announced they decided to stop vaccinations based on the recommendation of its independent data monitoring committee (IDMC).
Read More
